Diagonal Bio (DIABIO) Q2 2025 earnings summary

Executive summary

• Achieved key milestones in commercial and technical development, including the appointment of a Senior Commercial Advisor and progress in LAMPlify® system pilots.

• Advanced diagnostic tools for equine diseases, notably a new test for Streptococcus equi subs. equi.

• Filed a patent application for a computational method improving LAMP primer design, enhancing speed and performance.

• Secured full pre-subscription and underwriting commitments for TO 2 warrants, with a 59.3% exercise rate.

Financial highlights

• Net sales were 0 KSEK (0 KSEK year-over-year); capitalised development contributed 284 KSEK (284 KSEK).

• Net loss after financial items was -2,599 KSEK (-3,118 KSEK year-over-year); EPS was -0.002 SEK (-0.01 SEK).

• Cash flow for the quarter was 1,765 KSEK (2,302 KSEK year-over-year); cash at period end was 2,739 KSEK (4,158 KSEK).

• Investments in intangible assets totaled 98 KSEK (163 KSEK); no tangible asset investments this quarter (375 KSEK prior year).

Outlook and guidance

• Positioned for growth with momentum in commercial, technical, and financial areas.

• Focus on expanding LAMPlify® and Panviral® product families into new markets and applications.